Cover Image
市場調查報告書

惡性間皮癌:開發中產品分析

Malignant Mesothelioma - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 229749
出版日期 內容資訊 英文 511 Pages
訂單完成後即時交付
價格
Back to Top
惡性間皮癌:開發中產品分析 Malignant Mesothelioma - Pipeline Review, H1 2017
出版日期: 2017年03月31日 內容資訊: 英文 511 Pages
簡介

惡性間皮癌是一種少見的原發性肋膜惡性腫瘤。是常曝露於石棉下產生的癌症。惡性腫瘤會影響胸膜(被覆於肺與胸腔內側的平滑薄細胞膜)。由於腹膜間皮瘤起於腹部,常見的症狀有腹痛,體重減少,噁心,嘔吐等。同時也包含貧血、腸堵塞′胸痛、喀血等。

本報告提供惡性間皮癌的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

惡性間皮癌概要

治療藥的開發

  • 開發中產品:概要
  • 開發中的治療藥:各企業
  • 調查中的治療藥:各大學/研究機關
  • 開發中的產品:各企業
  • 調查中的產品:各大學/研究機關

治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

藥物簡介

暫停的計劃

開發中止的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9143IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Malignant Mesothelioma - Pipeline Review, H1 2017, provides an overview of the Malignant Mesothelioma (Oncology) pipeline landscape.

Malignant pleural mesothelioma is a rare cancer often diagnosed in people who have been exposed to high levels of asbestos. The malignancy affects the pleura, a thin membrane of lubricating cells that lines the lungs and chest wall. Peritoneal mesothelioma originates in the abdomen and as a result, symptoms often include abdominal pain, weight loss, nausea, and vomiting. Other symptoms include anemia, bowel obstructions, chest pain and hemoptysis.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Malignant Mesothelioma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Malignant Mesothelioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Malignant Mesothelioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Malignant Mesothelioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 5, 30, 27, 14 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 3, 7 and 6 molecules, respectively.

Malignant Mesothelioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Malignant Mesothelioma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Malignant Mesothelioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Malignant Mesothelioma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Malignant Mesothelioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Malignant Mesothelioma (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Malignant Mesothelioma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Malignant Mesothelioma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Malignant Mesothelioma - Overview
    • Malignant Mesothelioma - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Malignant Mesothelioma - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Malignant Mesothelioma - Companies Involved in Therapeutics Development
    • Aduro BioTech Inc
    • Advantagene Inc
    • Amphera BV
    • AnGes MG Inc
    • arGEN-X BV
    • ArQule Inc
    • AVEO Pharmaceuticals Inc
    • Bayer AG
    • Biogen Inc
    • Bionomics Ltd
    • Biotecnol Ltd
    • Boehringer Ingelheim GmbH
    • Boston Biomedical Inc
    • Bristol-Myers Squibb Company
    • Calithera Biosciences Inc
    • CanBas Co Ltd
    • CBT Pharmaceuticals Inc
    • Concordia International Corp
    • Eagle Pharmaceuticals Inc
    • Eisai Co Ltd
    • Eli Lilly and Company
    • EnGeneIC Ltd
    • EpiZyme Inc
    • F. Hoffmann-La Roche Ltd
    • Five Prime Therapeutics Inc
    • Genelux Corp
    • GlaxoSmithKline Plc
    • Horizon Pharma Plc
    • Inventiva
    • Juno Therapeutics Inc
    • Karyopharm Therapeutics Inc
    • MacroGenics Inc
    • MedImmune LLC
    • Merck & Co Inc
    • Merck KGaA
    • Millennium Pharmaceuticals Inc
    • MolMed SpA
    • Morphotek Inc
    • Novartis AG
    • Ono Pharmaceutical Co Ltd
    • OSE Immunotherapeutics
    • Oxford BioMedica Plc
    • Pharma Mar SA
    • Philogen SpA
    • Polaris Pharmaceuticals Inc
    • Progenra Inc
    • Seattle Genetics Inc
    • Sellas Inc
    • Targovax ASA
    • TRACON Pharmaceuticals Inc
    • TREAT U SA
    • UbiVac LLC
    • VasGene Therapeutics Inc
    • Verastem Inc
    • Virttu Biologics Ltd
    • Vyriad Inc
    • Y's Therapeutics Co Ltd
  • Malignant Mesothelioma - Drug Profiles
    • (epirubicin + staurosporine) - Drug Profile
    • alisertib - Drug Profile
    • amatuximab - Drug Profile
    • anetumab ravtansine - Drug Profile
    • ARGX-110 - Drug Profile
    • atezolizumab - Drug Profile
    • AV-203 - Drug Profile
    • avelumab - Drug Profile
    • bevacizumab - Drug Profile
    • BG-00001 - Drug Profile
    • birabresib - Drug Profile
    • BMS-986148 - Drug Profile
    • BNC-105 - Drug Profile
    • brentuximab vedotin - Drug Profile
    • CB-839 - Drug Profile
    • CBP-501 - Drug Profile
    • CBT-501 - Drug Profile
    • Cellular Immunotherapy for Oncology - Drug Profile
    • Cellular Immunotherapy to Target Mesothelin for Malignant Pleural Mesothelioma and Advanced Leukemia - Drug Profile
    • Cellular Immunotherapy to Target Mesothelin for Oncology - Drug Profile
    • Cellular Immunotherapy to Target WT1 for Oncology - Drug Profile
    • cisplatin - Drug Profile
    • CRS-207 - Drug Profile
    • CSG-MESO - Drug Profile
    • defactinib hydrochloride - Drug Profile
    • DFP-10825 - Drug Profile
    • doxorubicin hydrochloride - Drug Profile
    • DPV-001 - Drug Profile
    • durvalumab - Drug Profile
    • durvalumab + tremelimumab - Drug Profile
    • E-7449 - Drug Profile
    • emactuzumab - Drug Profile
    • enoblituzumab - Drug Profile
    • ESK-1 - Drug Profile
    • FL-118 - Drug Profile
    • FP-1039 - Drug Profile
    • galinpepimut-S - Drug Profile
    • ganetespib - Drug Profile
    • GEN-0101 - Drug Profile
    • Gene Therapy for Glioblastoma and Mesothelioma - Drug Profile
    • Gene Therapy for Malignant Pleural Effusion and Solid Tumors - Drug Profile
    • Gene Therapy to Activate NK4 for Malignant Pleural Mesothelioma - Drug Profile
    • GLONC-1 - Drug Profile
    • GSK-2256098 - Drug Profile
    • GSK-3359609 - Drug Profile
    • HSV-1716 - Drug Profile
    • HXR-9 - Drug Profile
    • iCasp9M28z - Drug Profile
    • interferon gamma-1b - Drug Profile
    • ipilimumab + nivolumab - Drug Profile
    • JTCR-016 - Drug Profile
    • KPT-251 - Drug Profile
    • KPT-276 - Drug Profile
    • LEU-001 - Drug Profile
    • lurbinectedin - Drug Profile
    • LY-3023414 - Drug Profile
    • MesoCancerVac - Drug Profile
    • MesoCART - Drug Profile
    • MGD-009 - Drug Profile
    • Monoclonal Antibody Conjugate to Target Mesothelin for Malignant Mesothelioma - Drug Profile
    • Monoclonal Antibody Conjugate to Target Mesothelin for Oncology - Drug Profile
    • MTG-201 - Drug Profile
    • MTG-202 - Drug Profile
    • napabucasin - Drug Profile
    • NGR-hTNF - Drug Profile
    • nintedanib - Drug Profile
    • nivolumab - Drug Profile
    • Oncolytic Virus for Malignant Pleural Mesothelioma - Drug Profile
    • Oncolytic Virus to Target CD46 and SLC5A5 for Malignant Pleural Mesothelioma - Drug Profile
    • ONCOS-102 - Drug Profile
    • OSE-2101 - Drug Profile
    • Oshadi D + Oshadi R - Drug Profile
    • OXB-301 - Drug Profile
    • P-0005091 - Drug Profile
    • pegargiminase - Drug Profile
    • pembrolizumab - Drug Profile
    • pemetrexed disodium - Drug Profile
    • porfimer sodium - Drug Profile
    • rAd-IFN - Drug Profile
    • RG-7787 - Drug Profile
    • S-588210 - Drug Profile
    • Small Molecule for Malignant Mesothelioma and Asbestosis - Drug Profile
    • Small Molecule for Oncology - Drug Profile
    • Stem Cell Therapy to Target TRAIL Receptor for Malignant Pleural Mesothelioma and Metastatic Lung Cancer - Drug Profile
    • TargomiRs - Drug Profile
    • tazemetostat - Drug Profile
    • TB-535 - Drug Profile
    • Teleukin - Drug Profile
    • tivantinib - Drug Profile
    • trabectedin - Drug Profile
    • TRC-102 - Drug Profile
    • Vaccine to target Mesothelin for Mesothelioma and Ovarian Cancer - Drug Profile
    • Vaccine to Target WT1 for Oncology - Drug Profile
    • Vas-01 - Drug Profile
    • YS-110 - Drug Profile
  • Malignant Mesothelioma - Dormant Projects
  • Malignant Mesothelioma - Discontinued Products
  • Malignant Mesothelioma - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Malignant Mesothelioma, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Malignant Mesothelioma - Pipeline by Aduro BioTech Inc, H1 2017
  • Malignant Mesothelioma - Pipeline by Advantagene Inc, H1 2017
  • Malignant Mesothelioma - Pipeline by Amphera BV, H1 2017
  • Malignant Mesothelioma - Pipeline by AnGes MG Inc, H1 2017
  • Malignant Mesothelioma - Pipeline by arGEN-X BV, H1 2017
  • Malignant Mesothelioma - Pipeline by ArQule Inc, H1 2017
  • Malignant Mesothelioma - Pipeline by AVEO Pharmaceuticals Inc, H1 2017
  • Malignant Mesothelioma - Pipeline by Bayer AG, H1 2017
  • Malignant Mesothelioma - Pipeline by Biogen Inc, H1 2017
  • Malignant Mesothelioma - Pipeline by Bionomics Ltd, H1 2017
  • Malignant Mesothelioma - Pipeline by Biotecnol Ltd, H1 2017
  • Malignant Mesothelioma - Pipeline by Boehringer Ingelheim GmbH, H1 2017
  • Malignant Mesothelioma - Pipeline by Boston Biomedical Inc, H1 2017
  • Malignant Mesothelioma - Pipeline by Bristol-Myers Squibb Company, H1 2017
  • Malignant Mesothelioma - Pipeline by Calithera Biosciences Inc, H1 2017
  • Malignant Mesothelioma - Pipeline by CanBas Co Ltd, H1 2017
  • Malignant Mesothelioma - Pipeline by CBT Pharmaceuticals Inc, H1 2017
  • Malignant Mesothelioma - Pipeline by Concordia International Corp, H1 2017
  • Malignant Mesothelioma - Pipeline by Eagle Pharmaceuticals Inc, H1 2017
  • Malignant Mesothelioma - Pipeline by Eisai Co Ltd, H1 2017
  • Malignant Mesothelioma - Pipeline by Eli Lilly and Company, H1 2017
  • Malignant Mesothelioma - Pipeline by EnGeneIC Ltd, H1 2017
  • Malignant Mesothelioma - Pipeline by EpiZyme Inc, H1 2017
  • Malignant Mesothelioma - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
  • Malignant Mesothelioma - Pipeline by Five Prime Therapeutics Inc, H1 2017
  • Malignant Mesothelioma - Pipeline by Genelux Corp, H1 2017
  • Malignant Mesothelioma - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Malignant Mesothelioma - Pipeline by Horizon Pharma Plc, H1 2017
  • Malignant Mesothelioma - Pipeline by Inventiva, H1 2017
  • Malignant Mesothelioma - Pipeline by Juno Therapeutics Inc, H1 2017
  • Malignant Mesothelioma - Pipeline by Karyopharm Therapeutics Inc, H1 2017
  • Malignant Mesothelioma - Pipeline by MacroGenics Inc, H1 2017
  • Malignant Mesothelioma - Pipeline by MedImmune LLC, H1 2017
  • Malignant Mesothelioma - Pipeline by Merck & Co Inc, H1 2017
  • Malignant Mesothelioma - Pipeline by Merck KGaA, H1 2017
  • Malignant Mesothelioma - Pipeline by Millennium Pharmaceuticals Inc, H1 2017
  • Malignant Mesothelioma - Pipeline by MolMed SpA, H1 2017
  • Malignant Mesothelioma - Pipeline by Morphotek Inc, H1 2017
  • Malignant Mesothelioma - Pipeline by Novartis AG, H1 2017
  • Malignant Mesothelioma - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017
  • Malignant Mesothelioma - Pipeline by OSE Immunotherapeutics, H1 2017
  • Malignant Mesothelioma - Pipeline by Oxford BioMedica Plc, H1 2017
  • Malignant Mesothelioma - Pipeline by Pharma Mar SA, H1 2017
  • Malignant Mesothelioma - Pipeline by Philogen SpA, H1 2017
  • Malignant Mesothelioma - Pipeline by Polaris Pharmaceuticals Inc, H1 2017
  • Malignant Mesothelioma - Pipeline by Progenra Inc, H1 2017
  • Malignant Mesothelioma - Pipeline by Seattle Genetics Inc, H1 2017
  • Malignant Mesothelioma - Pipeline by Sellas Inc, H1 2017
  • Malignant Mesothelioma - Pipeline by Targovax ASA, H1 2017
  • Malignant Mesothelioma - Pipeline by TRACON Pharmaceuticals Inc, H1 2017
  • Malignant Mesothelioma - Pipeline by TREAT U SA, H1 2017
  • Malignant Mesothelioma - Pipeline by UbiVac LLC, H1 2017
  • Malignant Mesothelioma - Pipeline by VasGene Therapeutics Inc, H1 2017
  • Malignant Mesothelioma - Pipeline by Verastem Inc, H1 2017
  • Malignant Mesothelioma - Pipeline by Virttu Biologics Ltd, H1 2017
  • Malignant Mesothelioma - Pipeline by Vyriad Inc, H1 2017
  • Malignant Mesothelioma - Pipeline by Y's Therapeutics Co Ltd, H1 2017
  • Malignant Mesothelioma - Dormant Projects, H1 2017
  • Malignant Mesothelioma - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Malignant Mesothelioma - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Malignant Mesothelioma, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Top 10 Routes of Administration, H1 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2017
  • Number of Products by Top 10 Molecule Types, H1 2017
  • Number of Products by Stage and Top 10 Molecule Types, H1 2017
Back to Top